Trial Profile
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Enobosarm (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Sponsors GTx
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 11 Dec 2020 Primary endpoint has been met. (Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects in 9 mg group)
- 11 Dec 2020 Primary endpoint has been met. (Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects in 18 mg group)